Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors
Zubairi, Ishtiaq Husain, Dean, Emma Jane, Molife, L Rhoda, Lopez, Juanita Suzanne, Ranson, Malcolm, El-Khouly, Fatima, Savulsky, Claudio Isaac, Reyderman, Larisa, Jia, Yan, Hutton, Emily, Morrison, Rosemary, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca Sophie, Evans, T.R. Jeffry
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer
Nasim, Muhammad Yaser, Plummer, Ruth, Evans, T.R. Jeffry, Morrison, Rosemary, Anthoney, David Alan, Haney, Sophie, Madi, Ayman, Savulsky, Claudio Isaac, Johnston, Claire, Carter, David, Reyderman, Larisa, Gopalakrishna, Prashanth, Wanders, Jantien, Twelves, Christopher
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article